Major Analyst Actions Under Review: Fidelity National Information Services, Inc. (FIS), Cyclacel Pharmaceuticals, Inc. (CYCC)

The recently concluded session had traders exchanging Fidelity National Information Services, Inc. (NYSE:FIS) low level. Roughly 0.81 million shares changed hands compared to the three-month volume average 1.23 million shares. The first trade took place at $95.84 and the stock went down -0.46% to attain the closing price of $95.27.

Fidelity National Information Services, Inc. (FIS) Analyst Opinion

Fidelity National Information Services, Inc. has a consensus outperform rating from 23 Wall Street analysts, and the number of shares currently sold short amount to at least 0.72% of shares outstanding. The stock spiked 2.63% last month and is up 25.95 this year. Wall Street is only getting more bullish on the stock, with 20 of analysts who cover FIS having a buy-equivalent rating. Analysts have placed a $101.52 price target on Fidelity National Information Services, Inc., suggesting a 6.56% gain from recent close. It’s currently trading about -0.76% below its 52-week high.

Fidelity National Information Services, Inc. Earnings Surprise

Fidelity National Information Services, Inc. (FIS) surprised the stock market in its last reported earnings when it earned $1.02 a piece versus the consensus-estimated $0.97. Its revenue totaled $2.35 billion up 4.09% from the previous quarter.

Fidelity National Information Services, Inc. (NYSE:FIS) Intraday View

This stock (FIS) is ahead of its 52-week low with 30.06%. Its last month’s stock price volatility remained 0.82% which for the week stands at 0.71%. The share price has moved forward from its 20 days moving average, trading at a distance of 1.12% and stays 2.56% away from its 50 days moving average. Over the last five days, shares have managed 0.94% gains and now is up 10.91% since hitting its 200-day moving average of $88.43. Fidelity National Information Services, Inc. (FIS) has made its way to a 12-month gain of 25.52%.

Turning to Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), its shares were trading at $1.93 a gain of $0.02, on the trading floor. The stock, after opening at $1.92, touched a high of $2.01 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2. Cyclacel Pharmaceuticals, Inc. tumbled -82.29% from its high of $ 10.90 to a $21.96 million market value through last close.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Intraday Trading

The counter witnessed a trading volume of 0.38 million shares versus an average volume of 0.64 million shares during last trading session. Its last month’s stock price volatility remained 4.16% which for the week approaches 6.26%. The lowest price the stock reached in the last trading day was $1.89 and compares with the $1.56 52-week low. The stock recovered 23.72% since its low point and has performed -63.52% year-to-date.

SHARE